In light of those results, Szűcs and Soltész (2010), in an arithmetic verification task, decreased the proportion of correct trials to 40% in order to decrease the perceived subjective probability.
Registration validity and completeness were evaluated using percentage of microscopic verification (MV) index (the proportion of incident cases with histological and/or cytological verification of cancer diagnosis) and percentage of death certificates only (DCO) (the proportion of incident cases with information based on death certificates only).
The result verification shows that concrete mix proportion performance evaluation using SC is reliable and the difference is within an acceptable range of accuracy of 5% difference.
Supplementary Table III gives the number of cancers (all ages), relative frequencies, average annual crude, age-adjusted incidence rates (AAR), and proportion of microscopic verification by site (ICD-10) and sex (2003 2008) of the PBCR, Sikkim.
The proportion of histological verification of FBC was generally high with a range of 92.5 to 96.8% and for cases of metachronous primary breast cancer with up to 100% confirmation.
A relatively low proportion of morphological verification is in part, however, the result of highly qualified medical personnel using radiological and other less costly evidence for determining cancer diagnoses; cases more often present with metastatic disease.
Based on "Guideline of Chinese Cancer Registration" and the standard of data inclusion in "Cancer Incidence in Five Continents Volume IX" [2], cancer registration data were evaluated by the following quality indicators: proportion of morphologic verification (MV%), percentage of cancer cases identified with death certification only (DCO%), and mortality-to-incidence ratio (M/I) [3]– [5].
The proportion of morphologic verification (MV%), the percentage of cancer cases identified by death certification only (DCO%), the mortality-to-incidence ratio (M/I), the percentage of uncertified cancer (UB%), and the percentage of cancer with undefined or unknown primary site (secondary) (O&U%) were used to evaluate the completeness, validity, and reliability of the cancer registration data.
Based on the guideline of Chinese cancer registration [8] and the standard of data inclusion in Cancer Incidence in Five Continents Volume IX [9], cancer registration data were evaluated by several quality indicators: proportion of morphologic verification (MV%), percentage of cancer cases identified with death certification only (DCO%), and mortality/incidence ratio (M/I) [10]– [10].
